Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
IDEAYA Biosciences $92 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Alnylam Pharmaceuticals $1.035 billion convertible senior notes offering
The 1% convertible notes are due 2027
Immunocore $250 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
Novo Nordisk $1.1 billion acquisition of Forma Therapeutics
We are advising Novo Nordisk on the transaction
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Blackstone and CPPIB $1.96 billion Advarra acquisition financing
We advised the lead arrangers and initial term lenders on the financing
Assertio $70 million convertible senior notes offering
The 6.5% notes are due 2027
Freeman Spogli investment in EverVet
We advised Tailwind Capital and EverVet on the transaction
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff
Oak Street Health $180.3 million secondary offering
We advised the joint book-running managers on the equity offering